The British Society for Allergy and Clinical Immunology (BSACI) have produced a new guideline for the diagnosis and management of peanut and tree nut allergy. This detailed document brings together the latest research and expert views and is aimed at healthcare professionals. Patients will benefit from receiving the latest evidence based advice, including better understanding of risk assessment in order to reduce accidental reactions and manage reactions more effectively.
The Anaphylaxis Campaign was contacted by the BSACI earlier this year and asked to comment on the draft copy of their nut guideline. We found the document overall to be a very useful and comprehensive best practice guidance for the diagnosis and management of peanut and tree nut allergy. We did however suggest a number of proposed changes, most of which were incorporated into the final draft and also expressed our concern about and disagreement with, the BSACI stance on how many adrenaline injectors should be prescribed. Anaphylaxis Campaign has always advocated, and will continue to advocate for two injectors to be available at all times for anyone who has been assessed as needing to carry adrenaline. This is in line with advice from both the Medicines and Healthcare Products Regulatory Agency (MHRA) and the European Medicines Agency (EMA).